title: Reply: To PMID 25068637.
authors: Nagoya, Japan.
authors: Yuichiro
authors: Y
authors: Ogura
authors: Kiel, Germany.
authors: Johann
authors: J
authors: Roider
authors: Bordeaux, France.
authors: Jean-François
authors: JF
authors: Korobelnik
authors: Bonn, Germany.
authors: Frank G
authors: FG
authors: Holz
authors: Vienna, Austria.
authors: Christian
authors: C
authors: Simader
authors: Vienna, Austria.
authors: Ursula
authors: U
authors: Schmidt-Erfurth
authors: Tarrytown, New York.
authors: Robert
authors: R
authors: Vitti
authors: Tarrytown, New York.
authors: Alyson J
authors: AJ
authors: Berliner
authors: Berlin, Germany.
authors: Florian
authors: F
authors: Hiemeyer
authors: Berlin, Germany and Erlangen-Nürnberg, Germany.
authors: Brigitte
authors: B
authors: Stemper
authors: Berlin, Germany and Hamburg, Germany.
authors: Oliver
authors: O
authors: Zeitz
authors: Berlin, Germany and Düsseldorf, Germany.
authors: Rupert
authors: R
authors: Sandbrink
mesh_terms: D005260:Female; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012170:Retinal Vein Occlusion / Q000150:complications*
chemical_list: D011993:Recombinant Fusion Proteins; D040262:Receptors, Vascular Endothelial Growth Factor